Phase 2b study of COYA101 for the yreatment of amyotrophic lateral sclerosis

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 31 Mar 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Mar 2023 According to a Coya Therapeutics media release, Initiate this Phase 2b study with grant funding or collaborative partnership in 2024.
01 Dec 2021 New trial record
16 Nov 2021 According to a Coya Therapeutics media release, the company held a Type B Pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration (FDA) and received a positive response supporting the planned clinical development strategy. The company expects to file an IND in the second half of 2022 and anticipates initiating this trial shortly after.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com